Overview

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer
Phase:
PHASE2
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Treatments:
130-nm albumin-bound paclitaxel
Gemcitabine